Evidence for and Against Subclinical Disease Activity and Progressive Disease in MOG Antibody Disease and Neuromyelitis Optica Spectrum Disorder

被引：0
|
作者：
Molazadeh, Negar
Filippatou, Angeliki G.
Vasileiou, Eleni S.
Levy, Michael
Sotirchos, Elias S.
机构：
来源：
NEUROLOGY | 2022年 / 99卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S74 / S74
页数：1
相关论文
共 50 条
  • [1] Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder
    Molazadeh, Negar
    Filippatou, Angeliki G.
    Vasileiou, Eleni S.
    Levy, Michael
    Sotirchos, Elias S.
    JOURNAL OF NEUROIMMUNOLOGY, 2021, 360
  • [2] MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder
    Narayan, Ram
    Simpson, Alexandra
    Fritsche, Katelyn
    Salama, Sara
    Pardo, Santiago
    Mealy, Maureen
    Paul, Friedemann
    Levy, Michael
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 25 : 66 - 72
  • [3] MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?
    de Seze, Jerome
    BRAIN, 2017, 140 : 3072 - 3075
  • [4] Soluble TREM2 distinguishes neuromyelitis optica spectrum disorder from MOG antibody disease
    Chuquisana, Omar
    Spatola, Marianna
    Dinoto, Alessandro
    Sepulveda, Maria
    Mariotto, Sara
    Tintore, Mar
    Montalban, Xavier
    Comabella, Manuel
    Lunemann, Jan D.
    BRAIN, 2024, 148 (02) : e4 - e7
  • [5] Long-term Efficacy and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease
    Barreras, P.
    Vasileiou, E.
    Filippatou, A.
    Fitzgerald, K.
    Levy, M.
    Mowry, E. M.
    Calabresi, P.
    Sotirchos, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 145 - 146
  • [6] Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease
    Barreras, Paula
    Vasileiou, Eleni S.
    Filippatou, Angeliki G.
    Fitzgerald, Kathryn C.
    Levy, Michael
    Pardo, Carlos A.
    Newsome, Scott D.
    Mowry, Ellen M.
    Calabresi, Peter A.
    Sotirchos, Elias S.
    NEUROLOGY, 2022, 99 (22) : E2504 - E2516
  • [7] Aquaporin-4-neuromyelitis optica spectrum disorder is not a progressive disease
    Villoslada, Pablo
    Sanchez-Dalmau, Bernardo
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (02): : 116 - 117
  • [8] Investigating neutrophil death in neuromyelitis optica and MOG-antibody disease
    Castagno, Maria Schroeder
    Suarez, Silvina Romero
    Serrato, Alba Del Rio
    Gonzalez, Cesar Alvarez
    Duchow, Ankelien Solveig
    Strobl, Judith Bellmann
    Paul, Friedemann
    Duarte, Carmen Infante
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 364 - 364
  • [9] Aquaporin-4 antibody neuromyelitis optica spectrum disorder: A paraneoplastic disease?
    Abdel-Mannan, Omar
    Hacohen, Yael
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (01) : 163 - 164
  • [10] Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging
    Cortese, Rosa
    Carrasco, Ferran Prados
    Tur, Carmen
    Bianchi, Alessia
    Brownlee, Wallace
    De Angelis, Floriana
    de la Paz, Isabel
    Grussu, Francesco
    Haider, Lukas
    Jacob, Anu
    Kanber, Baris
    Magnollay, Lise
    Nicholas, Richard S.
    Trip, Anand
    Yiannakas, Marios
    Toosy, Ahmed T.
    Hacohen, Yael
    Barkhof, Frederik
    Ciccarelli, Olga
    NEUROLOGY, 2023, 100 (03) : E308 - E323
12345